Compare iShares Silver Trust (SLV) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Silver Trust vs Twist Bioscience Corp — how do they compare? iShares Silver Trust trades at $55.05 (market cap $29.02B), while Twist Bioscience Corp trades at $159 (market cap $10.08B). The key difference: iShares Silver Trust is far larger — about 2.9× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, iShares Silver Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Silver Trust for 89 Days and Twist Bioscience Corp for 27 Days on average.
| SLV | TWST | |
|---|---|---|
Market Cap | $29.02B | $10.08B |
Volume | 16,510,334 | 4,229,037 |
52-Week High | $105.57 | $205.00 |
52-Week Low | $42.40 | $25.45 |
Typical Hold Time | 89 Days | 27 Days |
Sector | — | Health |
Enterprise Value | — | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLV trades at $55.06, up 2.3% over 24 hours, with a bearish technical signal from moving averages but neutral oscillators. The company reported $2.17M net income for 2024 despite zero revenue, with total assets surging to $13.41B from $10M in 2023. Recent news highlights silver price volatility driven by Fed policy expectations and Treasury yields.
The outlook is clouded by bearish technicals and macroeconomic pressures on silver, though low debt and asset growth offer stability. Risks include interest rate sensitivity and industrial demand fluctuations, while institutional sentiment remains cautious amid price declines.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
